Executive summary
US Drug Patent 9,700,575 claims protection for (i) high-purity cangrelor (or salts) formulated at near-neutral to mildly basic pH (7.0 to 9.5) with tight degradation-impurity specifications (combined selected hydrolysis/oxidation degradants ≤ 1.5% w/w, with dependent ranges down to ≤1.3%, and multiple impurity cutoffs for impurities A-E), and (ii) packaging in sealed vessels under chemically inert dry gas (nitrogen or argon) with ≤5% moisture over ≥6 months and specified 12-month stability endpoints for pH, moisture, and impurity limits. The estate is fundamentally a formulation-and-stability patent, with claim scope concentrated on quality attributes (purity/degradants/moisture) and process-adjacent container conditions (inert dry gas).
What is US Patent 9,700,575 and what does it claim about high-purity cangrelor formulations?
Answer: US 9,700,575 claims a pharmaceutical formulation comprising high purity cangrelor (or salt) plus excipients, with pH 7.0–9.5, a limit on selected hydrolysis and oxidation degradants (≤1.5% w/w, with dependent limits), defined impurity A-E thresholds, optional polyol excipients (mannitol/sorbitol), a specific drug-to-excipient weight ratio (about 16–21% cangrelor and 84–79% excipients), and a sealed-vessel/inert dry gas stability package (nitrogen/argon) with moisture ≤5% over at least 6 months and 12-month pH/moisture/impurity stability criteria.
Claim architecture: independent claims and the practical “landing zones”
The claims provided show two independent formulation families and one independent packaging family, with overlapping limitations:
-
Formulation core (Claim 1)
- High purity cangrelor (or salt) + pharmaceutically acceptable excipients
- pH 7.0–9.5
- Selected hydrolysis/oxidation degradants ≤1.5% w/w
- Selected degradants identified as impurity members (A-E listed in dependents)
-
Dependent narrowing (Claims 2–7)
- Degradants ≤1.3% (Claim 2)
- Impurities A–E individual cutoffs (Claim 3)
- Max impurity A and D each <0.5% (Claim 4)
- Excipients restricted to polyol (Claim 5)
- Excipients restricted to mannitol and sorbitol (Claim 6)
- Approximate composition window: 16–21% cangrelor and 84–79% excipients (Claim 7)
-
Alternative formulation species (Claim 14)
- “Consisting of” cangrelor + mannitol and/or sorbitol
- Same pH and degradant/impurity specification structure
- This “consisting of” phrasing narrows excipient permissiveness relative to the open “comprising” formulation in Claim 1
-
Packaging and stability (Claims 8–13 and 21–26)
- A sealed vessel containing the formulation
- Under chemically inert dry gas (nitrogen or argon in dependents)
- Moisture remains <5% for ≥6 months
- 12-month characterization includes:
- pH 7.0–9.5 for a 1% solution
- moisture <5%
- impurity limits:
- “A–D not exceeding about 1% each and E ≤0.5%” (Claim 11)
- or combined A–E ≤5% (Claim 12)
- or combined A–E ≤2% (Claim 13)
- Packaging family also parallels Claim 21–26 tied to Claim 14 formulation “consisting of” species
What the claims are really controlling: quality attributes more than generic formulation design
This patent is not about broad “cangrelor + excipient” combinations. It is about meeting a specific analytical profile:
- pH window (7.0–9.5) for a 1% solution (explicitly in stability claims)
- Maximum degradant burden from hydrolysis and oxidation
- Explicit impurity thresholds for multiple named/numbered impurities (A–E), with both individual and combined limits
- Moisture control using inert dry gas, with measurable stability outcomes at 6 and 12 months
Which excipients and composition ranges are covered by US 9,700,575 for cangrelor?
Answer: The claim set narrows to polyols and, in dependent claims, specifically mannitol and sorbitol, plus a composition window of roughly 16–21% high purity cangrelor and 84–79% total polyol excipients by weight.
Excipients: “polyol” and “mannitol/sorbitol” fall-through vs “consisting of”
- Claim 5: excipient is a polyol
- Claim 6: excipients are mannitol and sorbitol
- Claim 14: “pharmaceutical formulation consisting of” cangrelor + mannitol and/or sorbitol
- This “consisting of” language generally blocks additional excipients beyond those identified in the claim (absent arguments based on “impurities” or incidental components)
Composition window (weight percent)
- Claim 7 / Claim 20: formulation comprises about 16–21% high purity cangrelor and about 84–79% excipients by weight
- Practically, the patent covers a fairly high excipient-to-drug ratio typical of solid dispersions/excipients, lyophilized/powder compositions, or carrier-based solids, depending on the broader application record.
How do the pH and degradation-impurity limits define claim scope for cangrelor stability?
Answer: The claim scope is anchored on a tight pH band (7.0–9.5) and on quantitative degradant/impurity limits tied to hydrolysis and oxidation pathways.
Core quantitative limits
- pH: between about 7.0 and about 9.5
- Selected hydrolysis and oxidation degradants: ≤ about 1.5% w/w in Claim 1, with dependent tightening to ≤1.3% (Claim 2)
- Individual impurities A–E (Claim 3):
- impurity A < 0.5% w/w
- impurity B < 0.2% w/w
- impurity C < 0.3% w/w
- impurity D < 0.2% w/w
- impurity E < 0.5% w/w
- Max impurity A and D (Claim 4): each < 0.5% w/w
Stability endpoint framing
In the sealed-vessel claims, stability is measured by:
- Moisture: remains below 5.0% over at least 6 months
- 12 months: a suite of parameters is checked together:
- pH remains 7.0–9.5 (for 1% solution by weight)
- moisture <5%
- impurity profile meets one of multiple limiting schemes (A–D each ≤1% and E ≤0.5%; or combined A–E ≤5%; or combined A–E ≤2%)
What are the covered degradants (hydrolysis/oxidation) and how do the dependent impurity claims narrow infringement risk?
Answer: The claims constrain infringement by requiring that the formulation’s selected hydrolysis and oxidation degradants fall within defined bounds and that impurities A–E meet strict quantitative thresholds. Dependent claims reduce the design space by tightening either the total degradant burden (1.3% cap) or individual/combined impurity thresholds.
Claim-dependent “infringement funnels”
- Broadest filtration (Claim 1):
- total selected degradants ≤ 1.5% w/w
- Next tier (Claim 2):
- total selected degradants ≤ 1.3% w/w
- Impurity-specific floors (Claim 3 & 4):
- A–E individual limits
- plus A and D maximum each under 0.5%
- 12-month packaging outcome gating (Claims 11–13 / 24–26):
- multiple alternative endpoints define whether a formulation “works” under inert dry gas over 12 months
Practical implication for competitors
A generic or reformulation strategy that materially changes:
- pH,
- moisture control approach,
- excipient system away from mannitol/sorbitol polyols,
- or the analytical impurity profile for hydrolysis/oxidation pathways,
would aim to fall outside one or more numeric gating conditions.
Do the sealed vessel and nitrogen/argon inert dry gas terms materially expand the patent’s scope?
Answer: Yes. The packaging/stability claims create a separate infringement theory focused on container atmosphere and shelf-stability under inert dry gas, with explicit nitrogen/argon species and measurable moisture retention thresholds.
What the sealed-vessel claims require
- A sealed vessel containing the formulation
- Under chemically inert dry gas
- Nitrogen or argon (Claim 9 and Claim 22)
- Moisture <5.0% over ≥6 months (Claim 10 and Claim 23)
What happens after 12 months: multiple alternative “pass” tests
- Claim 11: pH 7.0–9.5 (1% solution); moisture <5%; impurities A–D each ≤1%; impurity E ≤0.5%
- Claim 12: combined impurities A–E ≤5%
- Claim 13: combined impurities A–E ≤2%
- Parallel structure under Claim 21–26 for the “consisting of” formulation species
What is the likely claim strength profile for US 9,700,575 based on claim specificity?
Answer: Claim strength is driven by highly specific numeric and compositional limitations (pH, total degradants, individual impurity cutoffs, moisture thresholds, and 6- and 12-month endpoints). That specificity can help enforceability by narrowing what counts as the patented formulation and stability performance.
Enforcement-relevant specificity
- Tight numeric thresholds:
- total degradants ≤1.5% and ≤1.3%
- moisture <5% for specified periods
- pH 7.0–9.5 for 1% solution
- impurity-specific cutoffs and combined caps (≤5% and ≤2%)
- Composition constraint:
- polyol excipients and mannitol/sorbitol limits
- weight range for active-to-excipient ratio
- Packaging environment:
- sealed vessel with inert dry gas and explicit nitrogen/argon
Litigation-inclined hinge points
In disputes, the most likely technical battlegrounds are:
- whether a product’s degradant set matches the claim’s “selected hydrolysis and oxidation degradants”
- whether measured impurity levels align with thresholds at relevant times and conditions
- whether moisture testing and storage atmosphere match the inert dry gas requirement
How does US 9,700,575 compare with typical cangrelor patent themes: formulation vs method vs packaging?
Answer: Based on the provided claims, 9,700,575 is squarely in the formulation + stability/packaging category. It does not appear to claim dosing regimens, therapeutic methods, or broad synthetic routes in the claim text provided.
Category split implied by claim content
- Formulation: defined by pH, degradants, impurities, excipients, and drug/excipient ratios
- Packaging: defined by sealed vessel atmosphere (dry inert gas) and stability outcomes (moisture and impurity/pH after storage)
What would a generic entry or reformulation risk look like under the US claims provided?
Answer: Risk concentrates on products that reproduce the patented quality profile and inert dry gas packaging conditions, especially where competitors attempt to match cangrelor’s degradation/impurity control strategy.
Highest-risk product scenarios
- Same or similar formulation meeting:
- pH 7.0–9.5
- selected hydrolysis/oxidation degradants ≤1.5% (or ≤1.3%)
- impurity A–E below the specified cutoffs
- excipients restricted to polyols, especially mannitol/sorbitol
- similar weight percent composition (16–21% cangrelor)
- Same or similar packaging:
- sealed vessel with nitrogen/argon dry gas
- moisture retained <5% for ≥6 months
- 12-month pH/moisture/impurity outcomes within the numeric schemes
Lower-risk routes (conceptual, based on claim requirements)
- Use alternative excipient systems outside “polyol” or beyond “mannitol and/or sorbitol” where the claim is “consisting of”
- Accept different pH outside 7.0–9.5, or different degradant/impurity profiles beyond the stated thresholds
- Use different packaging atmosphere or moisture control approach such that moisture exceeds <5% for the relevant period or fails 12-month impurity caps
What is missing from the provided claim text, and why it matters for a complete patent landscape?
Answer: The claim text alone does not provide the complete patent landscape for US 9,700,575. A landscape normally requires at least the patent’s bibliographic data and claims not supplied here (for example, filing/issue dates, priority chain, full claim set, continuations, related family members, and prosecution history). Without that dataset, it is not possible to build an authoritative US exclusivity/timeline, Orange Book mapping, or inter-patent freedom-to-operate chart.
(Per instruction constraints, this section reflects the limitation of the user-provided inputs.)
Key Takeaways
- US 9,700,575 protects high-purity cangrelor formulations defined by pH 7.0–9.5 and strict limits on selected hydrolysis/oxidation degradants (≤1.5% w/w; tightened dependent ≤1.3%).
- The patent tightly controls impurity A–E using both individual cutoffs and combined caps (in stability claims).
- Excipients are constrained to polyols, with dependent claims specifically requiring mannitol and sorbitol; an independent “consisting of” claim restricts excipients further to mannitol and/or sorbitol.
- Separate claim scope targets sealed-vessel packaging under inert dry gas (nitrogen/argon) with moisture <5% over ≥6 months and specified 12-month stability endpoints.
- In infringement analysis, the highest-friction elements are the analytical quality attributes (degradants/impurities) and the packaging atmosphere/moisture performance rather than broad formulation concept coverage.
FAQs
1) What analytical tests would most directly determine whether a product meets US 9,700,575?
Moisture content (including over ≥6 months), pH of a 1% solution, and impurity/degradant quantification for the specified hydrolysis and oxidation degradant set and impurities A–E.
2) Does the “consisting of” language in Claim 14 narrow excipient design freedom compared with Claim 1?
Yes. “Consisting of” limits the formulation ingredients to cangrelor and mannitol and/or sorbitol, which narrows inclusion of additional excipients versus “comprising.”
3) If a product meets the pH and impurity specs but uses a different atmosphere than nitrogen/argon, does it avoid the sealed-vessel claims?
Potentially, because the sealed-vessel claims specifically require chemically inert dry gas and narrow embodiments to nitrogen or argon in dependent claims.
4) How do the two different 12-month impurity schemes (≤5% vs ≤2% combined A–E) affect competition risk?
They create multiple “compliance bands.” A competitor must demonstrate failure to meet the relevant scheme tied to the asserted claim.
5) Can a reformulation change pH outside 7.0–9.5 and still infringe?
The independent formulation and stability claims explicitly require pH in the 7.0–9.5 range, so shifting pH outside the band is a primary way to fall outside the claim.
References
- United States Patent US 9,700,575.
